title: Clinicopathologic analysis of 22 cases of subcutaneous panniculitis-like CD56- or CD56+ lymphoma and review of 44 other reported cases.
abstract: In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9%]); tumor invasion in the superficial dermis (1 [9%]); erythrophagocytosis (10 [91%]); and medium-sized (11 [100%]), CD8+ (10 [91%]), T-cell receptor (TcR)betaF1+ (10 [91%]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82%]); tumor invasion in the superficial dermis (8 [73%]); erythrophagocytosis (1 [9%]); and pleomorphic large (10 [91%]), CD8+ (2/10 [20%]), TcRbetaF1 + (3/10 [30%]), and CD95 (Fas)+ (7/10 [70%]) tumor cells. These 7 factors were significantly different between groups (P < .01). Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRbetaF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was gamma/delta T-cell phenotype, 3 were alpha/beta T-cell, and 6 were TcRbetaF1- and gamma/delta- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.
authors.affiliation: Department of Pathology, National Kyushu Medical Center, Fukuoka, Japan.
authors.forename: Morishige
authors.initials: M
authors.lastname: Takeshita
authors.forename: Shuhei
authors.initials: S
authors.lastname: Imayama
authors.forename: Yumi
authors.initials: Y
authors.lastname: Oshiro
authors.forename: Kenji
authors.initials: K
authors.lastname: Kurihara
authors.forename: Sumika
authors.initials: S
authors.lastname: Okamoto
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Matsuki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nakashima
authors.forename: Takashi
authors.initials: T
authors.lastname: Okamura
authors.forename: Motoaki
authors.initials: M
authors.lastname: Shiratsuchi
authors.forename: Toru
authors.initials: T
authors.lastname: Hayashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kikuchi
mesh_terms: D000328:Adult; D015139:Blotting, Southern; D019002:CD56 Antigen / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D017403:In Situ Hybridization; D008223:Lymphoma / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015434:Panniculitis / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D040521:Subcutaneous Tissue / Q000378:metabolism / Q000473:pathology*
chemical_list: D019002:CD56 Antigen